An Open-label, Rapid Initiation Study for Extended-Release Buprenorphine Subcutaneous Injection (SUBLOCADE)
Phase: PHASE4
Conditions: Opioid-use Disorder
Sponsor: Indivior Inc.

Study Protocol 
 
NCT03993392 
 
Study Number:  INDV-6000-403 
 
Title:  An Open-label, Rapid Initiation Study for Extended-Release 
Buprenorphine Subcutaneous Injection (SUBLOCADE™) 
 
Protocol Date:  14 August 2019